Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. MIACALCIC
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MIACALCIC

Medicine - Posted on Oct 02 2020 - Updated on Oct 02 2020
Active substance (DCI)
  • calcitonine de saumon
history (4)
  • 9/9/20

    MIACALCIC

    Key points Unfavourable opinion for reimbursement in the MA indications; i.e.: prevention of acute bone loss associated with...
    CAV :
    54321
    icône flèche
  • 12/18/13

    MIACALCIC (calcitonine de saumon)

    MIACALCIC (calcitonine de saumon)
    icône flèche
  • 12/7/11

    MIACALCIC (calcitonine de saumon)

    MIACALCIC (calcitonine de saumon)
    icône flèche
  • 6/10/09

    MIACALCIC (calcitonine de saumon)

    Pas d’intérêt clinique démontré dans la prévention de la perte osseuse Médicaments de seconde intention dans le traitement d...
    icône flèche
Technical information
ATC code
  • H05BA01
Manufacturer
ESSENTIAL PHARMACEUTICALS
Presentation

MIACALCIC 50 U.I./1 ml, solution injectable ou pour perfusion (code CIS : 64577819)
5 ampoule(s) en verre de 1 ml (CIP : 34009 330 203 2 3)

All our publications
    Bone and cartilage diseases Cancers - miscellaneous Congenital, genetic and rare diseases Drug therapy Metabolic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
CZGjDBQdeXtxtEM0